SynthesisPloS one2018
Prognostic value of presepsin in adult patients with sepsis: Systematic review and meta-analysis.
Synthesis in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparison of presepsin and Mid-regional pro-adrenomedullin in the diagnosis of sepsis or septic shock: a systematic review and meta-analysis.BMC infectious diseases · 2023Pooled it
- Is Pleural Fluid Presepsin a Reliable Diagnostic Biomarker for Pleural Effusions?Diagnostics (Basel, Switzerland) · 2026Article
- Serial Presepsin Measurement as a Predictor of In-Hospital Mortality in Older Adults with Hip Fractures.Life (Basel, Switzerland) · 2026Article
- Prognostic Value of 48-Hour Biomarker Reassessment Beyond Admission SOFA for 28-Day Mortality in Sepsis.Diagnostics (Basel, Switzerland) · 2026Article
- Multi-Marker Approach in Sepsis: A Clinical Role Beyond SOFA Score.Medicina (Kaunas, Lithuania) · 2026Article
- Narrative Review: Research Progress and Future Directions of Presepsin in Neurological Prognostication of Adult Post-Return of Spontaneous Circulation (Post-ROSC) Cardiac Arrest Survivors.Journal of inflammation research · 2026Review
- Sepsis biomarkers: recent advances and future perspectives.Frontiers in immunology · 2026Review
- Early Sepsis Detection in Adult Patients with Suspected Sepsis in an Emergency Setting: A Sequential Strategy of Monocyte Distribution Width and Presepsin.Diagnostics (Basel, Switzerland) · 2025Article
- The Burden of Sepsis and Septic Shock in the Intensive Care Unit.Journal of clinical medicine · 2025Review
- The potential role of leukocytes cell population data (CPD) for diagnosing sepsis in adult patients admitted to the intensive care unit.Clinical chemistry and laboratory medicine · 2025Observational
- Evaluation of Presepsin for Early Diagnosis of Sepsis in the Emergency Department.Journal of clinical medicine · 2025Article
- Biomarkers Affecting Treatment Outcomes of Febrile Neutropenia in Hematological Patients with Lymphomas: Is Presepsin the New Promising Diagnostic and Prognostic Biomarker?Journal of clinical medicine · 2025Article
- Crossing Age Boundaries: The Unifying Potential of Presepsin in Sepsis Diagnosis Across Diverse Age Groups.Journal of clinical medicine · 2024Review
- Interleukin-6 and Procalcitonin as Potential Predictors of Acute Kidney Injury Occurrence in Patients with Sepsis.Reports of biochemistry & molecular biology · 2024Article
- Presepsin as a biomarker of bacterial translocation and an indicator for the prescription of probiotics in cirrhosis.World journal of hepatology · 2024Article
- No Significant Differences in Presepsin Levels According to the Causative Microorganism of Bloodstream Infection.Infection & chemotherapy · 2024Article
- Gut Microbiota and Biomarkers of Endothelial Dysfunction in Cirrhosis.International journal of molecular sciences · 2024Article
- Biomarkers in sepsis-looking for the Holy Grail or chasing a mirage!World journal of critical care medicine · 2023Review
- Utility of Presepsin and Interferon-λ3 for Predicting Disease Severity and Clinical Outcomes in COVID-19 Patients.Diagnostics (Basel, Switzerland) · 2023Article
- The Value of Peripheral Blood Leukocyte Parameters in the Early Diagnosis and Clinical Prognosis of Sepsis.International journal of analytical chemistry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePresepsin is a novel biomarker to diagnose sepsis but its prognostic value has not been comprehensively reviewed. We conducted this meta-analysis to evaluate the mortality prediction value of presepsin in sepsis.
methodsWe searched comprehensive electronic databases from PubMed, EMBASE, and Cochrane Library through September 2017 using the key words of ('presepsin' or 'sCD14-ST' or 'soluble CD14 subtype') and ('sepsis' or 'septic shock') and ('prognosis' or 'prognostic value' or 'prognostic biomarker' or 'mortality'). We extracted the presepsin levels in survivors and non-survivors from each individual study and evaluated the standardized mean difference (SMD) using a web-based meta-analysis with the R statistical analysis program.
resultsA total of 10 studies and 1617 patients were included. Presepsin levels in the first sampling (within 24 hours) were significantly lower among survivors as compared with non-survivors: the pooled SMD between survivors and non-survivors was 0.92 (95% CI: 0.62-1.22) in the random effects model (I2 = 79%, P< 0.01). In subgroups, divided by the sepsis severity or study site, pooled SMD was consistently noting higher presepsin levels in non-survivals (P< 0.05).
conclusionThis meta-analysis demonstrates some mortality prediction value in presepsin in patients with sepsis. Further studies are needed to define the optimal cut-off point to predict mortality in sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.